BioSpace News Archive

Biomarkers are vital for identifying diseases in the human body. They are vital to the healthcare sector. The use of biomarkers in drug development also plays a vital role in the discovery of various drugs and vaccines necessary for curing a specific disease or disorder.

LogicBio Therapeutics, Inc., a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, announced that its 2020 Annual Meeting of Stockholders will be held in a virtual-only format due to continued public health concerns related to coronavirus / COVID-19, and to support the health and well-being of our stockholders and other meeting participants.

Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, announced that management will participate in the Virtual Summer Summit, which is being held from June 9th-12th.

Menlo Therapeutics Inc., a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, announced the pricing of an underwritten public offering of 27,050,000 shares of common stock at a price to the public of $1.85 per share.

The sessions may be accessed from the “Investors & Media” page of Regeneron’s website at http://investor.regeneron.com/events-and-presentations.

Retinitis pigmentosa, is a condition where patients typically loses ability to see at night in young years, side vision in middle age, and focal vision in later in his/her life due to relentless loss of cone photoreceptor cells.

Extremity reconstruction implies the restoration of limbs and limb functions to patients who have suffered the removal of limbs due to trauma or medical removal after cancer or other issues.

Transparency Market Research has published a new report titled, “Psoriatic Arthritis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global psoriatic arthritis therapeutics market was valued at US$ 6,011.7 Mn in 2017.

According to the report, the global plaque modification devices market was valued at ~US$ 1.1 Bn in 2018 and is projected to expand at a high CAGR during the forecast period.

The motion sickness treatment market has evolved steadily over the years driven by expanding scope of pharmacologic therapy.